BigHat raises $75M for AI protein design

BigHat Biosciences raised $75 million in Series C funding on September 24, bringing total capital to $223 million, according to its financing announcement. The AI protein-design company says the round will advance BHB810, already in Phase 1, and BHB299 toward human trials in 2027. For builders evaluating AI drug discovery, Enveda’s clinical-evidence gate is the right ledger: capital buys the next experiment, not proof that a therapeutic works.